Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the company. Truist Financial downgraded Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. HC Wainwright reissued a “neutral” rating and set a $2.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Royal Bank of Canada reduced their price target on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Price Performance

MRNS stock opened at $0.54 on Wednesday. The firm has a 50 day simple moving average of $0.41 and a two-hundred day simple moving average of $0.95. The stock has a market cap of $29.96 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $10.50.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in MRNS. Point72 DIFC Ltd bought a new position in shares of Marinus Pharmaceuticals during the second quarter valued at about $28,000. AQR Capital Management LLC raised its position in Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter worth approximately $64,000. World Investment Advisors LLC bought a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth approximately $104,000. Finally, Deltec Asset Management LLC purchased a new position in shares of Marinus Pharmaceuticals during the fourth quarter valued at approximately $107,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.